“The COVID-19 pandemic could be an opportunity for the companies pursuing the development of gene therapies, as few products are in development to fight the viral illness.” Alessio Brunello of GlobalData
“We have heard how difficult it has been to find standards and want to make it as easy as possible for the industry and suppliers to find the standards that can make product development and manufacturing processes more efficient.” Robert Shaw of SCB
“Gene therapy has huge potential. It has already led to cures for conditions such as spinal muscular atrophy (SMA). In the future, we will be looking at conditions like motor neurone disease, Alzheimer’s and rare cancers,”
Advances in genomics research increased the speed with which vaccines came to the fore to mitigate infection by the SARS-CoV-2 virus, thanks to early sequencing of the virus. Here is a quick roundup of some recent genomics news related to COVID-19.
CKD is a slow and progressive loss of kidney function over several years, which can eventually cause permanent kidney failure. CKD often goes undetected and undiagnosed until the disease is well advanced, and the damage is irreversible resulting in poor survival rates. There are estimated to be 700 million cases of CKD worldwide, and currently there is no cure.
Findings showed that Previse could predict the onset of AKI up to 48 hours in advance of onset, sooner than the standard hospital systems like XGBoost AKI prediction model and the Sequential Organ Failure Assessment (SOFA).
Topline data from a recent Eli Lilly clinical trial indicate that tirzepatide led to superior A1C and body weight reductions from baseline compared to injectable semaglutide in adults with type 2 diabetes.